MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a worldwide leader in specialized, analysis-driven pharmaceutical-high quality cannabis extraction, distillation and derivative solutions, right now announced it will provide cannabis concentrate solutions in Denmark to two new health-related cannabis shoppers beneath two separate white-label agreements. These shoppers will be serviced by each GMP authorized facilities, MediPharm Labs Inc. and MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”). This marks MediPharm Labs’ initially provide agreements for the export of completed solutions to Denmark.
Denmark granted sufferers legal access to cannabis-primarily based medicinal solutions two years ago as component of a 4-year pilot system. The system offers sufferers with protected item access and national wellness authorities with patient information that they can use to realize usage and efficacy. According to data complied by New Frontier Information and the Danish Ministry of Well being, more than two,one hundred sufferers (mostly females involving the ages of 42-64) received cannabis-primarily based medicinal solutions from 429 prescribing physicians beneath this system in 2019.
“The express objective of establishing a multi-jurisdictional, GMP-certified production capability is to lead the worldwide cannabis market place for medicinal, wellness and adult use applications and these agreements represent yet another step forward in realizing our ambitions,” mentioned Pat McCutcheon, CEO, MediPharm Labs. “Getting in on the ground floor of the Danish health-related market place with new and revolutionary health-related cannabis focused solutions positions us for added development in Europe and adds to MediPharm Labs all-crucial physique of know-how that we are leveraging to improve the style of our formulations for sufferers and customers everywhere.”
Beneath the agreements, one particular which has an initial two-year term and the second a one particular-year term – each topic to renewal, MediPharm Labs will provide a complete variety of specially formulated CBD and THC cannabis oil solutions that will be white-labeled for distribution.
MediPharm Labs anticipates delivery to its shoppers to start in October 2020, pending regulatory approval by applicable wellness authorities.
GMP Certification Ignites Development for MediPharm Labs Australia
“Since the starting of 2020, MediPharm Labs Australia has secured a number of pretty desirable domestic and international provide agreements with higher high quality partners, now which includes new shoppers in Denmark,” mentioned Warren Everitt, CEO, MediPharm Labs Australia. “This volume and the pace of new organization wins are a clear and crucial validation of our selection to develop a GMP certified cannabis extraction facility provide chain for globe markets and a testament to MediPharm Labs expanding profile and reputation. We appear forward to ramping up production beneath all of these agreements.”
MediPharm Labs Australia received its Great Manufacturing Practice (“GMP”) certificate from the Therapeutic Goods Association in Might 2020, which enables it to sell cannabis APIs and completed solutions to nations across the EU, which includes Denmark. The Organization entered into its initially European white-label cannabis provide agreement that exact same month with Therismos Restricted.
About Denmark’s Healthcare Cannabis Industry
Denmark launched its 4-year health-related cannabis pilot system on January 1st, 20181. Post-harvest Great Manufacturing Processes (GMP) is essential for distribution of health-related cannabis solutions in Denmarktwo.
By way of the system, physicians can prescribe health-related cannabis for all purposes and are guided by suggestions in 4 places: discomfort brought on by several sclerosis, discomfort brought on by spinal cord harm, side effects from chemotherapy therapy and neuropathic discomfort that is due to brain, spinal cord or nerve harmthree. The recommendations published by the Danish Medicines Agency are primarily based on an comprehensive critique of literature as effectively as assessments of: cannabis schemes in the Netherlands, Canada and Israel preceding cannabis drug approvals in Europe and the US and scientific proof by the National Academy of Sciences (USA, 2017).
About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical high quality cannabis oil and concentrates and sophisticated derivative solutions using a Great Manufacturing Practices certified facility with ISO normal constructed clean rooms. MediPharm Labs has invested in an specialist, analysis-driven group, state-of-the-art technologies, downstream purification methodologies and objective-constructed facilities with 5 principal extraction lines for delivery of pure, trusted and precision -dosed cannabis solutions for its shoppers. By way of its wholesale and white label platforms, they formulate, customer-test, approach, package and distribute cannabis extracts and sophisticated cannabinoid-primarily based solutions to domestic and international markets. As a worldwide leader, MediPharm Labs has completed industrial exports to Australia and is nearing commercialization of its Australian Extraction facility. MediPharm Labs Australia was established in 2017.
For additional data, please get in touch with:
Laura Lepore, VP, Investor Relations
Phone: 705-719-7425 ext 1525
E mail: [email protected]
Internet site: www.medipharmlabs.com
1 Medicinal Cannabis Pilot Plan. Retrieved: https://laegemiddelstyrelsen.dk/en/unique/medicinal-cannabis/citizens/medicinal-cannabis-pilot-programme/
two The Healthcare Cannabis Industry in Denmark & Europe. Retrieved: https://www.openaccessgovernment.org/the-health-related-cannabis-market place-in-denmark-europe/80721/
three The Danish Healthcare Cannabis Pilot Programme: Placing the Patient 1st. Retrieved: https://www.healtheuropa.eu/the-danish-health-related-cannabis-pilot-programme-placing-the-patient-initially/92991/
CAUTIONARY NOTE Concerning FORWARD-Searching Information and facts:
This news release consists of “forward-searching information” and “forward-searching statements” (collectively, “forward-searching statements”) inside the which means of the applicable Canadian securities legislation. All statements, other than statements of historical truth, are forward-searching statements and are primarily based on expectations, estimates and projections as at the date of this news release. Any statement that requires discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or overall performance (generally but not often employing phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that specific actions, events or final results “may” or “could”, “would”, “might” or “will” be taken to take place or be accomplished) are not statements of historical truth and may possibly be forward-searching statements. In this news release, forward-searching statements relate to, amongst other items, the profitable overall performance of the agreements and shipping of solutions thereunder as planned added development in Europe and enhancing the style of formulations. Forward-searching statements are necessarily primarily based upon a quantity of estimates and assumptions that, though regarded affordable, are topic to identified and unknown dangers, uncertainties, and other variables which may possibly result in the actual final results and future events to differ materially from these expressed or implied by such forward-searching statements. Such variables consist of, but are not restricted to: common organization, financial, competitive, political and social uncertainties the inability of MediPharm Labs to receive sufficient financing the delay or failure to obtain regulatory approvals and other variables discussed in MediPharm Labs’ filings, accessible on the SEDAR web-site at www.sedar.com. There can be no assurance that such statements will prove to be precise, as actual final results and future events could differ materially from these anticipated in such statements. Accordingly, readers need to not location undue reliance on the forward-searching statements and data contained in this news release. Except as essential by law, MediPharm Labs assumes no obligation to update the forward-searching statements of beliefs, opinions, projections, or other variables, need to they adjust.